177 related articles for article (PubMed ID: 10873082)
1. Comparison of potential markers of farnesyltransferase inhibition.
Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH
Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
4. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
O'Meara SJ; Kinsella BT
Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
[TBL] [Abstract][Full Text] [Related]
6. Drugs affecting prelamin A processing: effects on heterochromatin organization.
Mattioli E; Columbaro M; Capanni C; Santi S; Maraldi NM; D'Apice MR; Novelli G; Riccio M; Squarzoni S; Foisner R; Lattanzi G
Exp Cell Res; 2008 Feb; 314(3):453-62. PubMed ID: 18093584
[TBL] [Abstract][Full Text] [Related]
7. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Adjei AA; Erlichman C; Davis JN; Cutler DL; Sloan JA; Marks RS; Hanson LJ; Svingen PA; Atherton P; Bishop WR; Kirschmeier P; Kaufmann SH
Cancer Res; 2000 Apr; 60(7):1871-7. PubMed ID: 10766174
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
9. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
12. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
13. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
14. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
[TBL] [Abstract][Full Text] [Related]
15. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Glass TL; Liu TJ; Yung WK
Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
18. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
20. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]